1. Home
  2. OBDC vs RARE Comparison

OBDC vs RARE Comparison

Compare OBDC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBDC
  • RARE
  • Stock Information
  • Founded
  • OBDC 2015
  • RARE 2010
  • Country
  • OBDC United States
  • RARE United States
  • Employees
  • OBDC N/A
  • RARE N/A
  • Industry
  • OBDC Investment Managers
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • OBDC Finance
  • RARE Health Care
  • Exchange
  • OBDC Nasdaq
  • RARE Nasdaq
  • Market Cap
  • OBDC 5.8B
  • RARE 5.2B
  • IPO Year
  • OBDC 2019
  • RARE 2014
  • Fundamental
  • Price
  • OBDC $15.07
  • RARE $46.02
  • Analyst Decision
  • OBDC Hold
  • RARE Strong Buy
  • Analyst Count
  • OBDC 8
  • RARE 14
  • Target Price
  • OBDC $15.64
  • RARE $86.79
  • AVG Volume (30 Days)
  • OBDC 1.6M
  • RARE 974.4K
  • Earning Date
  • OBDC 11-06-2024
  • RARE 11-05-2024
  • Dividend Yield
  • OBDC 10.16%
  • RARE N/A
  • EPS Growth
  • OBDC N/A
  • RARE N/A
  • EPS
  • OBDC 1.61
  • RARE N/A
  • Revenue
  • OBDC $1,613,593,000.00
  • RARE $522,745,000.00
  • Revenue This Year
  • OBDC $2.52
  • RARE $27.29
  • Revenue Next Year
  • OBDC $5.12
  • RARE $18.30
  • P/E Ratio
  • OBDC $9.34
  • RARE N/A
  • Revenue Growth
  • OBDC 6.06
  • RARE 27.44
  • 52 Week Low
  • OBDC $13.98
  • RARE $37.02
  • 52 Week High
  • OBDC $16.91
  • RARE $60.37
  • Technical
  • Relative Strength Index (RSI)
  • OBDC 55.04
  • RARE 34.61
  • Support Level
  • OBDC $14.86
  • RARE $43.04
  • Resistance Level
  • OBDC $14.95
  • RARE $53.04
  • Average True Range (ATR)
  • OBDC 0.19
  • RARE 2.14
  • MACD
  • OBDC 0.02
  • RARE -0.35
  • Stochastic Oscillator
  • OBDC 83.46
  • RARE 28.57

About OBDC Blue Owl Capital Corporation

Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: